Drug Trial Radar · NCT07901933
Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Oct 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Cajal Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b, randomized, double-blinded, placebo-controlled study of CTX001 in participants with anemia and chronic kidney disease who are not on dialysis.
Conditions
- Chronic Kidney Disease
- Anemia
Interventions
PlaceboDrug
Matching placebo administered orally once daily for 29 days.
CTX001Drug
CTX001 administered orally at the assigned cohort dose once daily for 29 days.
Ferrous SulfateDrug
Ferrous sulfate administered orally once daily for 29 days in both treatment arms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: From first administration of study intervention through the end of study participation, around Day 36.
- Incidence of Serious TEAEsTime frame: From first administration of study intervention through the end of study participation, around Day 36.
- Incidence of Clinically Significant Changes in Physical ExaminationTime frame: From first administration of study intervention through the end of study participation, around Day 36.
- Incidence of Clinically Significant Changes in Safety Laboratory ValuesTime frame: From first administration of study intervention through the end of study participation, around Day 36.
- Incidence of Clinically Significant Changes in Vital SignsTime frame: From first administration of study intervention through the end of study participation, around Day 36
- Incidence of Clinically Significant Changes in ElectrocardiogramsTime frame: From first administration of study intervention through the end of study participation, around Day 36
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Renal Research Gosford
Gosford, New South Wales, Australia
Royal North Shore Hospital
St Leonards, New South Wales, Australia
AOVO Clinical Trials
Southport, Queensland, Australia
Royal Perth Hospital
Perth, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.